Novartis presented new clinical data at the EULAR 2026 Congress in London, showcasing results from its immunology portfolio targeting autoimmune diseases such as polymyalgia rheumatica, Sjögren’s disease, systemic lupus erythematosus, and systemic sclerosis. Key highlights include Phase III trial results for Cosentyx in polymyalgia rheumatica, interim data for ianalumab in Sjögren’s disease, and early efficacy of CAR-T therapy rap-cel in severe inflammatory conditions. These findings demonstrate Novartis' commitment to innovative treatments addressing high unmet medical needs in immunology, potentially improving patient outcomes. The company plans to continue advancing these therapies through further clinical development and regulatory processes.
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMA...
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), regardless of disease volume or pre...
